AMLX Q2 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0+100.0% YoY

Gross Profit

-$141,000

Operating Income

-$43M

Net Income

-$41M

EPS (Diluted)

$-0.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$195M

Total Liabilities

$27M

Stockholders' Equity

$168M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	-$1M	+100.0%
Gross Profit	-$141,000	-$9M	+98.4%
Operating Income	-$43M	-$53M	+19.8%
Net Income	-$41M	-$73M	+43.0%